Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Chemotherapy, and EUS-RFA in Advanced Pancreatic Cancer
NCT06831136Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by UTHealth Houston. Primary endpoint: Overall Response Rate up to 12 months. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06831136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831136.